EAN 2026 | One big question with Richard Nowak: what MG advance could transform care in the next 3 years?

That’s a fantastic question, and I think that’s a question that might not have one specific answer to. I think one major impact that we can have in transforming care is a biomarker that predicts how an individual with myasthenia gravis might fare in terms of their outcomes and predict responsiveness to certain therapeutics that we have available to us. So currently, we have a great number of targeted therapies available to us. But the question that comes up, not only for clinicians treating patients with myasthenia gravis, is which medication to choose, when, and is this going to achieve clinical outcomes in our patients that we care for? And the answer is we don’t know unless we try the medication first. So a biomarker predicting treatment response is critically important and is currently a major knowledge gap. I would sort of add one additional thing to that in what I think can be very transformative, which is the induction of immune tolerance. So we have medications that can treat the underlying disease drivers, but we don’t have a way to restore immune balance for our patients. Looking at the dysregulation that occurs in all autoimmune conditions, including myasthenia gravis, if we had a way to have the immune system restore self-tolerance, we could essentially and effectively cure disease or have at least sustained and durable responses over time. That’s not in the next three years. I think that’s more of a long-term five- to ten-year potential transformative area. So getting back, I think biomarkers are really key and an unmet need at this point in time.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.